4.2 Article

Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers

Journal

PHARMACOGENOMICS
Volume 16, Issue 9, Pages 939-948

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/pgs.15.40

Keywords

CYP2C8; CYP2C9; ibuprofen; pharmacokinetics; polymorphisms

Funding

  1. Fundacion Teofilo Hernando, Universidad Autonoma de Madrid
  2. University Autonoma de Madrid (FPI)
  3. Abbott
  4. Alter
  5. Chemo
  6. Farmalider
  7. Ferrer
  8. GlaxoSmithKline
  9. Janssen-Cilag
  10. Kern
  11. Normon
  12. Novartis
  13. Servier
  14. Teva
  15. Zambon

Ask authors/readers for more resources

Aim: To evaluate the effect of polymorphisms in CYP2C9 and CYP2C8 and gender on the pharmacokinetics of the enantiomeric forms of ibuprofen. Materials & methods: 122 healthy volunteers were genotyped for polymorphisms in CY2C8 and CYP2C9 using real-time PCR. Results:CYP2C8 polymorphisms affected neither R- nor S-ibuprofen. CYP2C9*3 and CYP2C9*2 carriers had a lower S-ibuprofen clearance and a higher S-ibuprofen AUC and half-life. R-ibuprofen clearance was decreased in CYP2C9*3 carriers. Gender affected R-ibuprofen and S-ibuprofen pharmacokinetics. Multiple regression analysis showed that CYP2C9*2, CYP2C9*3 and gender were associated with S-ibuprofen clearance, but only CYP2C9*3 was associated with R-ibuprofen clearance. Conclusion: The pharmacokinetics of S-ibuprofen and R-ibuprofen is affected by CYP2C9 polymorphisms and gender. CYP2C8 polymorphisms do not have a significant role. Original submitted 6 February 2015; Revision submitted 1 April 2015

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available